Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
- Supplementary File 1:
PDF-Document (PDF, 140 KiB)
Louveau, B.; Jouenne, F.; Reger de Moura, C.; Sadoux, A.; Baroudjian, B.; Delyon, J.; Herms, F.; De Masson, A.; Da Meda, L.; Battistella, M.; Dumaz, N.; Lebbe, C.; Mourah, S. Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. Cancers 2019, 11, 1203. https://doi.org/10.3390/cancers11081203
Louveau B, Jouenne F, Reger de Moura C, Sadoux A, Baroudjian B, Delyon J, Herms F, De Masson A, Da Meda L, Battistella M, Dumaz N, Lebbe C, Mourah S. Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. Cancers. 2019; 11(8):1203. https://doi.org/10.3390/cancers11081203
Chicago/Turabian StyleLouveau, Baptiste; Jouenne, Fanelie; Reger de Moura, Coralie; Sadoux, Aurelie; Baroudjian, Barouyr; Delyon, Julie; Herms, Florian; De Masson, Adele; Da Meda, Laetitia; Battistella, Maxime; Dumaz, Nicolas; Lebbe, Celeste; Mourah, Samia. 2019. "Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care" Cancers 11, no. 8: 1203. https://doi.org/10.3390/cancers11081203